Vumon Related Published Studies
Well-designed clinical trials related to Vumon (Teniposide)
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. [2003.09.01]
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). [2002.09]
Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. [2000.10.01]
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. [1999.07]
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. [1998.06]
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. [1997.12.15]
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer. [1997.04]
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. [1996.10]
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. [1996.04]
Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. [1996.01]
Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study. [1995.03]
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). [1995.01]
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). [1995]
Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. [1994.09]
A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. [1994]
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancer. [1992.04]
Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. [1991.09]
A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. [1991.01]
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. [1990.07.15]
Well-designed clinical trials possibly related to Vumon (Teniposide)
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. [2008.01.20]
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. [2007.12]
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). [2006.10.15]
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. [2005.05.15]
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. [2005.04.20]
[Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases.] [2004.12]
A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. [2001.07]
Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. [2001.05]
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. [2001.01.03]
Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study. [2000.03.01]
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. [1999.12.01]
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. [1999.10]
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. [1999.03]
Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. [1998.07]
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. [1998.02.19]
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. [1997.08]
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. [1997]
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. [1995.11]
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. [1995.10]
[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients] [1995.07]
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update. [1995.02]
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. [1994.11.01]
Treatment of small cell lung cancer: the Copenhagen experience. [1994.01]
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. [1994]
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. [1994]
Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. [1993.11.25]
Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. [1993.11]
Chemotherapy induced nausea and emesis in pediatric cancer patients: external validity of child and parent emesis ratings. [1993.08]
Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. [1993.08]
Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. [1993.02.01]
Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. [1993.02]
Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. [1992.04]
Failure of intensive chemotherapy in poor prognosis non-Hodgkin's lymphoma. [1992.04]
Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. [1992.02]
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. [1991.12.12]
Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. [1991.10]
Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study. [1991.07.01]
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group. [1991.06]
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. [1991.05]
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. [1991.04]
Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. [1991.01.12]
Single versus multiple drug therapy in the combined treatment of malignant gliomas. A multicenter study. [1990.07]
A new treatment protocol for childhood non-Hodgkin's lymphoma: preliminary evaluation. [1990.04]
[Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol] [1990.02]
LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. [1989.08]
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. [1989.07]
High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. [1988]
Other research related to Vumon (Teniposide)
Determination of teniposide in rat plasma by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry after intravenous administration. [2009.09]
Chemical stability of teniposide in aqueous and parenteral lipid emulsions. [2009.04]
Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. [2009]
The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. [2007.10]
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). [2006.10.18]
[Chemotherapy with higher or lower dose of teniposide combined with cisplatin and pingyangmycin for oral squamous cell carcinoma] [2004.05]
Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. [2004]
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. [2003.12]
[Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer] [2002.12]
Other possibly related research studies
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. [2008.07.20]
Pulmonary complications of novel antineoplastic agents for solid tumors. [2008.02]
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. [2008.02]
Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas. [2007.09]
Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol. [2007.07]
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. [2007.02]
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. [2007.04]
Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. [2006.10]
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. [2006]
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. [2006.12.15]
Retinoblastoma in children older than 5 years of age. [2007.03]
[The interactions of antiepileptic drugs in oncology practice] [2006.06.01]
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. [2006]
Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. [2006.06]
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. [2005.12.01]
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. [2005.11.01]
[Standards and new developments in the chemotherapy of glioblastomas] [2005.10.07]
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. [2004.04]
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults] [2005.08.18]
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. [2006.02]
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. [2005.07.01]
Cardiotoxicity of cancer chemotherapy: implications for children. [2005]
Toxicity of the topoisomerase II inhibitors. [2005.03]
Chemotherapy for retinoblastoma. [2005.03]
Preradiation chemotherapy with VM-26 and CCNU in patients with glioblastoma multiforme. [2004.11]
Pharmacokinetic studies in children with cancer. [2004.12]
|
